This vulnerability (synthetic lethality) initially allowed pharmacological inhibition of PARP to be exploited in BRCA1/2 deficient cancer, which is now being extended to BRCA proficient cancer [3,4,5]. This evidence concerns the gene PARP1 and cancer.